Dong Hyun Gim

Dong Hyun Gim

Auto-generated profile, based on publicly available information

Dong Hyun Gim

Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea (J.M.L., D.H.G., D.K., K.H.C., T.K.P., J.H.Y., S.-Y.L., S.-H.C., H.-C.G., Y.B.S., J.-Y.H.).

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
SLSeung Hun Lee
Seung Hun Lee
DGDong Hyun Gim
Dong Hyun Gim
DHDoyeon Hwang
Doyeon Hwang
HKHyun Kuk Kim
Hyun Kuk Kim
HCHyun Cho
Hyun Cho
JLJoo Myung Lee
Joo Myung Lee
Background: Angiography‐based fractional flow reserve (FFR) techniques offer wire‐free alternatives but often require manual segmentation and 3‐dimensional reconstruction. Although an artificial intelligence‐driven approach automates these steps, validation remains limited. This study investigated the diagnostic performance of an artificial intelligence‐driven angiography‐based FFR (medipixel FFR [MPFFR]), compared with quantitative flow ratio (QFR) in predicting functionally significant coronary artery stenosis defined by FFR ≤0.80. Methods: A total of 599 vessels from 452 patients who underwent clinically indicated FFR measurement were prospectively enrolled from 5 university hospitals in Korea. MPFFR used automated processes in frame selection, artificial intelligence contour detection, corresponding points matching, 3‐dimensional reconstruction, and analytical hemodynamic modeling. The primary end point was diagnostic accuracy for detecting FFR ≤0.80. Secondary end points were target vessel failure (composite of cardiac death, target‐vessel myocardial infarction, and target‐vessel revascularization) at 2 years. Results: Mean analysis time of MPFFR was 12.5±1.7 seconds and manual correction was needed in 32 vessels (5.3%). MPFFR showed similar diagnostic performance with QFR (correlation with FFR; MPFFR versus QFR: R=0.885 versus R=0.860, P for comparison=0.011; area under the curve to predict FFR ≤0.80; 0.949 versus 0.953, P for comparison=0.631). At a median follow‐up of 2 years (interquartile range, 1.6–2.6 years), patients with MPFFR ≤0.80 had higher risk of target vessel failure than those with MPFFR >0.80 (4.5% versus 0.8%; adjusted hazard ratio, 5.94 [95% CI, 1.27–27.91]; P =0.024). C‐index to predict target vessel failure was comparable between MPFFR and QFR (0.770 versus 0.753, P for comparison=0.469). Conclusions: In this multicenter registry, an artificial intelligence‐driven angiography‐based FFR demonstrated comparable diagnostic accuracy with QFR in identifying functionally significant stenosis, and similar prognostic ability with QFR in terms of target vessel failure at 2 years. Registration: Multicenter QFR Registry; Unique Identifier: NCT03791788.

2 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
DGDong Hyun Gim
Dong Hyun Gim
YHYeonkyeong Han
Yeonkyeong Han
TPTaegyun Park
Taegyun Park
TPTaek Kyu Park
Taek Kyu Park
JLJoo Myung Lee
Joo Myung Lee
KCKi Hong Choi
Ki Hong Choi
Background: Smoking cessation after a diagnosis of type 2 diabetes mellitus (T2DM) lowers cardiovascular risk, but sustained abstinence is difficult and e-cigarettes are promoted as an alternative. Whether switching to e-cigarettes confers comparable benefit is unknown.Methods: This nationwide cohort study used the Korean National Health Insurance Service database. Adults aged 40–74 years newly diagnosed with T2DM between Jan 1, 2018, and Dec 31, 2023, who smoked at the examination preceding diagnosis were included. Self-reported behaviour at the first examination after diagnosis (the index date) defined three groups: quitters, e-cigarette users, and continued combustible cigarette users. The primary outcome was myocardial infarction. Hazard ratios were estimated with Cox proportional hazards models weighted by stabilised inverse probability of treatment weights (IPTW). This study is registered with ClinicalTrials.gov, NCT07414355.Findings: Of 164,859 participants, 31,539 were quitters, 36,801 were e-cigarette users, and 96,519 continued smoking. Over a median 2·1 years (IQR:1·1–3·4), myocardial infarction occurred at 0·8, 1·4, and 1·7 events per 1000 person-years, respectively. Compared with quitters, risk was higher in e-cigarette users (IPTW-adjusted HR:1·78, 95%CI:1·21–2·62) and in continued smokers (HR:2·17, 95%CI:1·66–2·83); risk in e-cigarette users did not differ from that in continued smokers (HR:0·82, 95%CI:0·61–1·12). The pattern was similar for coronary revascularisation (HR:1·26, 95%CI:1·00–1·60 for e-cigarette users and HR:1·23, 95%CI:1·07–1·42 for continued smokers, respectively). Continued smokers also had higher risks of ischaemic stroke (HR:1·20, 95%CI:1·03–1·39) and all-cause death (HR:1·49, 95%CI:1·28–1·73), whereas estimates for e-cigarette users were 0·98 (95%CI:0·72–1·33) and 1·04 (95%CI:0·77–1·42). Dual users, who comprised 24,987 (67·9%) of e-cigarette users, had a higher myocardial infarction risk than complete switchers (HR:2·03, 95%CI:1·17–3·53).Interpretation: Among adults with newly diagnosed T2DM who smoked, cessation was associated with the lowest risk of coronary events, and switching to e-cigarettes did not reproduce this benefit. Risks of stroke and death in e-cigarette users did not differ from those in quitters, but follow-up was short. E-cigarettes should not be regarded as equivalent to cessation after a diagnosis of T2DM.

29 October 2026 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
JLJoo Myung Lee
Joo Myung Lee
DGDong Hyun Gim
Dong Hyun Gim
YPYong Hwan Park
Yong Hwan Park
JLJong-Young Lee
Jong-Young Lee
JJJin-Ok Jeong
Jin-Ok Jeong
JHJoo-Yong Hahn
Joo-Yong Hahn
BACKGROUND: Clopidogrel monotherapy has shown superior efficacy compared with aspirin after completion of dual antiplatelet therapy following percutaneous coronary intervention (PCI). However, whether treatment effects differ according to overall atherothrombotic risk integrating clinical and angiographic factors remains unclear. METHODS: This post hoc analysis of the SMART-CHOICE 3 (Smart Angioplasty Research Team: Choice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3) randomized trial included patients who completed guideline-directed dual antiplatelet therapy after PCI. Atherothrombotic risk was defined using the a Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention and complex PCI. Patients with Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention ≥3 or complex PCI were classified as higher risk, and those with a Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention <3 without complex PCI were classified as lower risk. The primary end point was major adverse cardiac and cerebrovascular events (death, myocardial infarction, or stroke). Bleeding was defined as Bleeding Academic Research Consortium type 2, 3, or 5. RESULTS: Among 5506 patients, 4486 (81.5%) were at higher risk and 1020 (18.5%) were at lower risk. Over a median 2.3 years, the incidence of major adverse cardiac and cerebrovascular events was higher in the higher-risk group (6.1% versus 3.1%; hazard ratio, 1.83 [95% CI, 1.17–2.78]; P =0.007). In higher-risk patients, clopidogrel reduced major adverse cardiac and cerebrovascular events compared with aspirin (4.6% versus 7.4%; hazard ratio, 0.67 [95% CI, 0.50–0.89]; P =0.006), with no difference in lower-risk patients (3.0% versus 3.2%; hazard ratio, 1.03; P =0.945; interaction P =0.242). Bleeding was similar between groups. CONCLUSIONS: After completion of dual antiplatelet therapy following PCI, clopidogrel monotherapy was associated with lower ischemic risk than aspirin in patients with higher atherothrombotic risk, without increased bleeding. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04418479.